Answers are grounded in this paper and cite their sources.
The incidence of infections caused by methicillin-resistantStaphylococcus aureus (MRSA) continues to increase in many countries worldwide. Rapid identification of MRSA from clinical specimens and screening of high-risk patients for MRSA colonization have been found to be cost-effective measures for limiting the spread of the organism in hospitals (1, 6). Several screening media for the enhanced recovery of methicillin-resistant organisms and for the differentiation of S. aureus from coagulase-negative staphylococci have been developed (2, 4, 5, 7, 8). Recently, a novel medium, oxacillin resistance screening agar base (ORSAB; Oxoid Limited, Basingstoke, England), has been developed for the detection of MRSA in clinical specimens. The medium uses aniline blue to demonstrate mannitol fermentation in staphylococci. The dual antibiotic supplement (oxacillin, 2.0 μg/ml; polymixin B, 50,000 IU/l) and the presence of 5.5% NaCl have the potential to reduce the growth of nonstaphylococcal organisms and to select for the growth of MRSA. We evaluated the performance of ORSAB as compared to that of mannitol salt agar supplemented with 2.0 μg/ml oxacillin (MSA) for the recovery of MRSA from clinical specimens.
No takes yet. Share an insight, caveat, or question.
Simor et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: